Abstract
Background
We sought to study the association between brain natriuretic peptide (BNP) levels and the occurrence of ventricular arrhythmias in patients with left ventricular dysfunction (LVD) and an implantable cardioverter defibrillator (ICD).
Methods
This was a prospective study of consecutive, stable, ambulatory patients with moderate and severe ischemic LVD and an ICD. A plasma BNP level was obtained at recruitment. Patients were evaluated every 3–6 mo for a minimum of 1 y. The primary end point was the occurrence of malignant ventricular arrhythmia or sudden cardiac death (SCD).
Results
The cohort consisted of 94 subjects (6 women) with a mean ± standard deviation (SD) age of 69 ± 10 y. The ICD implantation indication was primary and secondary prevention of SCD in 49% and 51% of subjects, respectively. A primary end point occurred in 27 patients (29%), and was more frequent in symptomatic heart failure patients and those implanted for secondary prevention of SCD. The median BNP level was significantly higher among patients who experienced an end point (191 pg/ml versus 142 pg/ml, p = 0.03). After controlling for New York Heart Association heart failure class and ICD implantation indication, the odds ratio (OR) for experiencing an adverse outcome among the upper BNP quartile versus all others was 3.5 (95% confidence interval [CI]: 1.2–10.2). Among patients implanted for primary prevention of SCD, none of the patients in the lower BNP quartile (BNP < 91 pg/ml) experienced an adverse outcome.
Conclusions
These results suggest that abnormally high BNP levels not only predict cardiac death, but also arrhythmic death in this patient population, and a low BNP level can serve to identify low risk patients. Copyright © 2008 Wiley Periodicals, Inc.
Keywords: B‐type natriuretic peptide, sudden death, ventricular tachycardia, ventricular fibrillation, implantable cardioverter defibrillator
Full Text
The Full Text of this article is available as a PDF (106.8 KB).
References
- 1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators : A comparison of antiarrhythmic‐drug therapy with implantable defibrillators in patients resuscitated from near‐fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576–1578. [DOI] [PubMed] [Google Scholar]
- 2. Gold MR, Nisam S: Multicenter Automatic Defibrillator Implantation Trial, Multicenter Unsustained Tachycardia Trial. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: Lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol 2000; 23: 1981–1985. [DOI] [PubMed] [Google Scholar]
- 3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–883. [DOI] [PubMed] [Google Scholar]
- 4. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, et al.: Plasma natriuretic peptide levels and risk of cardiovascular events and death. N Engl J Med 2004; 350: 655–663. [DOI] [PubMed] [Google Scholar]
- 5. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, et al.: B‐type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392–2395. [DOI] [PubMed] [Google Scholar]
- 6. Tapanainen JT, Lindgren KS, Makikallio TH, Vulteenaho O, Leppaluoto J, et al.: Natriuretic peptides as predictors of non‐sudden and sudden cardiac death after acute myocardial infarction in the beta blocking era. J Am Coll Cardiol 2004; 43: 757–763. [DOI] [PubMed] [Google Scholar]
- 7. Manios EG, Kallergis EM, Kanoupakis EM, Mavrakis HE, Kambouraki DC, et al.: Amino‐terminal pro‐brian natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter‐defibrillators. Chest 2005; 128: 2604–2610. [DOI] [PubMed] [Google Scholar]
- 8. Verma A, Kilicaslan F, Martin DO, Minor S, Starling R, et al.: Preimplantation B‐type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006; 92: 190–195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Blangy H, Sadoul N, Dousset B, Radauceanu A, Fay R, et al.: Serum BNP, hs‐C‐reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace (Epub ahead of print; May 24, 2007). [DOI] [PubMed] [Google Scholar]
- 10. Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, et al., TOVA Investigators : Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: Results from the triggers of ventricular arrhythmias (TOVA) study. Circulation 2004; 109: 1386–1391. [DOI] [PubMed] [Google Scholar]
- 11. Kohl P, Bollensdorff C, Garny A: Effects of mechanosensitive ion channels on ventricular electrophysiology: Experimental and theoretical models. Exp Physiol 2006; 91: 307–321. [DOI] [PubMed] [Google Scholar]
- 12. Sanders GD, Hlatky MA, Owens DK. Cost‐effectiveness of implantable cardioverter‐defibrillators. N Engl J Med 2005;353: 1471–1480. [DOI] [PubMed] [Google Scholar]